PerspectivesTherapeutic Options for Recurrent High-Grade Gliomas: A Perspective Statement
References (21)
- et al.
The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma
World Neurosurg
(2011) - et al.
Therapeutic options in recurrent glioblastoma–An update
Crit Rev Oncol Hematol
(2016) - et al.
Therapy for recurrent high-grade gliomas: results of a prospective multicenter study on health-related quality of life
World Neurosurg
(2017) - et al.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Acta Neuropathol
(2016) - et al.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
N Engl J Med
(2005) - et al.
Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas
Acta Neurochir (Wien)
(2015) - et al.
Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection
Neuro Oncol
(2016) - et al.
A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma
Neuro Oncol
(2013) - et al.
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
N Engl J Med
(2015) - et al.
Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial
JAMA
(2015)
Cited by (4)
Surgical treatment of small recurrent gliomas based on MR imaging examination
2024, Medical Engineering and PhysicsExtensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype
2018, World NeurosurgeryCitation Excerpt :In this case report, we provide a detailed description of a patient with extensive intracranial and spinal leptomeningeal metastases of a supratentorial GBM, IDH-wildtype, and the salvage treatments applied over the course of the disease. Salvage treatment of recurrent or progressive GBMs is still mostly based on individualized decisions, as clear recommendations remain scarce.13 This is especially true for rare cases with spinal leptomeningeal metastases, for which sufficient data are lacking and appropriate experiences are available only in form of retrospective case series.4-7,14-20
In Reply to the Letter to the Editor “Probiotics: Novel Addition to Antiglioma Armamentarium”
2018, World NeurosurgeryProbiotics: Novel Addition to Antiglioma Armamentarium
2018, World Neurosurgery
Commentary on: Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life by Stöckelmaier et al. World Neurosurg 102:383-399, 2017